Entrada Therapeutics, Inc.

NasdaqGM:TRDA Stock Report

Market Cap: US$469.5m

Entrada Therapeutics Management

Management criteria checks 3/4

Entrada Therapeutics' CEO is Dipal Doshi, appointed in Aug 2017, has a tenure of 7.42 years. total yearly compensation is $3.74M, comprised of 15.7% salary and 84.3% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $1.64M. The average tenure of the management team and the board of directors is 3.8 years and 3.9 years respectively.

Key information

Dipal Doshi

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage15.7%
CEO tenure7.4yrs
CEO ownership0.3%
Management average tenure3.8yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

The Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26%

Jan 11
The Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26%

There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Oct 17
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Aug 23
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

Mar 19
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Nov 09
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 26
Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 14
Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

Mar 08
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02

Aug 11

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Dipal Doshi's remuneration changed compared to Entrada Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$55m

Jun 30 2024n/an/a

US$104m

Mar 31 2024n/an/a

US$23m

Dec 31 2023US$4mUS$585k

-US$7m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$80m

Dec 31 2022US$3mUS$565k

-US$95m

Sep 30 2022n/an/a

-US$88m

Jun 30 2022n/an/a

-US$78m

Mar 31 2022n/an/a

-US$64m

Dec 31 2021US$6mUS$425k

-US$51m

Sep 30 2021n/an/a

-US$41m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$906kUS$385k

-US$27m

Compensation vs Market: Dipal's total compensation ($USD3.74M) is above average for companies of similar size in the US market ($USD2.18M).

Compensation vs Earnings: Dipal's compensation has been consistent with company performance over the past year.

CEO

Dipal Doshi (48 yo)

7.4yrs

Tenure

US$3,735,466

Compensation

Mr. Dipal Doshi serves as Director of The Children's Health Fund. He serves as Director of Ashibio, Inc since September 2024. Mr. Doshi has been Chief Executive Officer and Director of Entrada Therapeutics...

Leadership Team

NamePositionTenureCompensationOwnership
Dipal Doshi
CEO & Director7.4yrsUS$3.74m0.35%
$ 1.6m
Nathan Dowden
President & COO5.2yrsUS$1.49m0.35%
$ 1.7m
Natarajan Sethuraman
President of Research & Development1yrUS$1.49m0.20%
$ 940.2k
Kory Wentworth
CFO & Treasurer4.2yrsno data0.21%
$ 979.2k
Jared Cohen
General Counsel4.8yrsno datano data
Kerry Robert
Senior Vice President of People3.4yrsno datano data
Karla MacDonald
Chief Corporate Affairs Officer2.5yrsno datano data
Kevin Healy
Senior Vice President of Regulatory Affairs1yrno datano data

3.8yrs

Average Tenure

50.5yo

Average Age

Experienced Management: TRDA's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dipal Doshi
CEO & Director7.4yrsUS$3.74m0.35%
$ 1.6m
Peter Kim
Director4.1yrsUS$192.12k0.29%
$ 1.4m
Mary Thistle
Industry Leader & Independent Director3.7yrsUS$211.18k0%
$ 0
Kush Parmar
Independent Chairman of the Board8.3yrsUS$237.58k0%
$ 0
Bernhardt G. Zeiher
Industry Leader & Independent Director1.8yrsUS$334.02k0%
$ 0
Gina Chapman
Independent Director1.3yrsUS$341.88k0%
$ 0

3.9yrs

Average Tenure

58.5yo

Average Age

Experienced Board: TRDA's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 00:28
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Entrada Therapeutics, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris ShibutaniGoldman Sachs
Raghuram SelvarajuH.C. Wainwright & Co.
Boobalan PachaiyappanH.C. Wainwright & Co.